AnaptysBio (ANAB) Competitors $22.14 +1.19 (+5.68%) Closing price 09/24/2025 04:00 PM EasternExtended Trading$22.16 +0.02 (+0.11%) As of 05:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANAB vs. GMTX, CGON, MLYS, IBRX, CPRX, ALVO, OCUL, BLTE, IDYA, and AGIOShould you be buying AnaptysBio stock or one of its competitors? The main competitors of AnaptysBio include Gemini Therapeutics (GMTX), CG Oncology (CGON), Mineralys Therapeutics (MLYS), ImmunityBio (IBRX), Catalyst Pharmaceuticals (CPRX), Alvotech (ALVO), Ocular Therapeutix (OCUL), Belite Bio (BLTE), IDEAYA Biosciences (IDYA), and Agios Pharmaceuticals (AGIO). These companies are all part of the "pharmaceutical products" industry. AnaptysBio vs. Its Competitors Gemini Therapeutics CG Oncology Mineralys Therapeutics ImmunityBio Catalyst Pharmaceuticals Alvotech Ocular Therapeutix Belite Bio IDEAYA Biosciences Agios Pharmaceuticals Gemini Therapeutics (NASDAQ:GMTX) and AnaptysBio (NASDAQ:ANAB) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk. Do analysts prefer GMTX or ANAB? AnaptysBio has a consensus target price of $46.13, indicating a potential upside of 108.33%. Given AnaptysBio's stronger consensus rating and higher probable upside, analysts clearly believe AnaptysBio is more favorable than Gemini Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00AnaptysBio 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.80 Which has preferable earnings & valuation, GMTX or ANAB? Gemini Therapeutics has higher earnings, but lower revenue than AnaptysBio. Gemini Therapeutics is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGemini TherapeuticsN/AN/A-$71.87M-$1.00-62.16AnaptysBio$91.28M6.79-$145.23M-$4.48-4.94 Does the media favor GMTX or ANAB? In the previous week, AnaptysBio had 2 more articles in the media than Gemini Therapeutics. MarketBeat recorded 3 mentions for AnaptysBio and 1 mentions for Gemini Therapeutics. AnaptysBio's average media sentiment score of 1.38 beat Gemini Therapeutics' score of 0.00 indicating that AnaptysBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gemini Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AnaptysBio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals believe in GMTX or ANAB? 75.4% of Gemini Therapeutics shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by company insiders. Comparatively, 33.5% of AnaptysBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, GMTX or ANAB? Gemini Therapeutics has a beta of -0.12, indicating that its stock price is 112% less volatile than the S&P 500. Comparatively, AnaptysBio has a beta of -0.19, indicating that its stock price is 119% less volatile than the S&P 500. Is GMTX or ANAB more profitable? Gemini Therapeutics has a net margin of 0.00% compared to AnaptysBio's net margin of -107.66%. Gemini Therapeutics' return on equity of -38.78% beat AnaptysBio's return on equity.Company Net Margins Return on Equity Return on Assets Gemini TherapeuticsN/A -38.78% -35.88% AnaptysBio -107.66%-366.98%-30.58% SummaryAnaptysBio beats Gemini Therapeutics on 10 of the 16 factors compared between the two stocks. Get AnaptysBio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANAB vs. The Competition Export to ExcelMetricAnaptysBioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$586.54M$3.14B$5.78B$10.41BDividend YieldN/A2.36%5.68%4.62%P/E Ratio-4.9420.7675.9926.42Price / Sales6.79402.55543.86179.21Price / CashN/A45.9137.5661.52Price / Book9.509.8312.956.39Net Income-$145.23M-$52.73M$3.29B$271.13M7 Day Performance5.03%1.84%0.81%0.93%1 Month Performance10.15%7.48%4.95%7.52%1 Year Performance-31.54%19.92%68.72%30.06% AnaptysBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANABAnaptysBio2.3161 of 5 stars$22.14+5.7%$46.13+108.3%-36.5%$586.54M$91.28M-4.94100Positive NewsGMTXGemini TherapeuticsN/A$59.82-0.8%N/A+32.4%$2.59BN/A-59.8230CGONCG Oncology2.5761 of 5 stars$34.60+3.8%$53.91+55.8%+0.4%$2.54B$1.14M-19.5561Insider TradeGap UpMLYSMineralys Therapeutics2.7079 of 5 stars$36.21-2.4%$43.50+20.1%+232.2%$2.46BN/A-10.1728Positive NewsIBRXImmunityBio2.3037 of 5 stars$2.74+5.4%$10.75+292.3%-30.6%$2.46B$14.74M-5.71590High Trading VolumeCPRXCatalyst Pharmaceuticals4.9418 of 5 stars$19.76-1.1%$33.20+68.0%-3.9%$2.44B$491.73M11.9880Positive NewsALVOAlvotech3.5031 of 5 stars$8.12+1.1%$14.00+72.4%-23.2%$2.42B$491.98M35.301,032Trending NewsAnalyst UpgradeOCULOcular Therapeutix3.9096 of 5 stars$12.54-2.1%$17.83+42.2%+46.2%$2.23B$63.72M-9.80230Positive NewsGap UpBLTEBelite Bio3.0324 of 5 stars$66.80-3.9%$96.00+43.7%+47.0%$2.21BN/A-43.1010High Trading VolumeIDYAIDEAYA Biosciences3.9905 of 5 stars$24.53-0.3%$42.85+74.7%-18.2%$2.16B$7M-6.4780AGIOAgios Pharmaceuticals4.2629 of 5 stars$36.30-1.3%$56.00+54.3%-19.9%$2.14B$36.50M3.30390 Related Companies and Tools Related Companies Gemini Therapeutics Competitors CG Oncology Competitors Mineralys Therapeutics Competitors ImmunityBio Competitors Catalyst Pharmaceuticals Competitors Alvotech Competitors Ocular Therapeutix Competitors Belite Bio Competitors IDEAYA Biosciences Competitors Agios Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANAB) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AnaptysBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AnaptysBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
